Date: 11.07.2024

To
The Manager
Corporate Relations Department
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai – 400001

Dear Sir/Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Sub: Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

We would like to inform that the Company has entered into a Loan Agreement dated 10-07-2024 to avail a loan amount of up to Rs 1,00,00,000/- (Rupees One Crore) in one or more tranches from Moki Financial Services (Partnership Firm) for the purpose of working capital requirements, general business purpose and Repayment of loan & liabilities of the Company.

The Company has received the signed copy of the loan agreement today on 11-07-2024 and accordingly, this intimation is being given to BSE today on 11-07-2024

In accordance with requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para B (5) of Part A of Schedule III and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, details attached herein shall be taken on record

Thanking You

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar (Company Secretary & Head-Legal)



Agreements (viz. loan agreement(s) or any other agreement(s) which are binding and not in normal course of business, revision(s) or amendment(s) and termination(s) thereof:

Sr. No	Particulars	Details
1	Name(s) of parties with whom the agreement is entered;	1. Company – Pharmaids Pharmaceuticals Limited ("Borrower") and 2. Moki Financial Services ("Moki") ("Lender") ("Related party of the Company") Dr. Shankarappa Nagaraja Vinaya Babu, the Chairman and Non-Executive Director of the Company is a partner in Moki Financial Services, consequently, Moki is considered as related party of the Company.
2	Purpose of entering into the agreement;	To avail Loan for the general business purpose, working capital requirements and Repayment of loan & liabilities.
3	Size of agreement	Loan amount of up to Rs 1,00,00,000/- (Rupees One Crore Only) to be availed in one or more tranches.
4	Shareholding, if any, in the entity with whom the agreement is executed;	Nil
5	Significant terms of the agreement (in brief); special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	Interest Rate: 12% p.a. The loan is to be given for a maximum period of 5 years from the date of disbursement or such timeline as mutually decided between the parties.
6	Whether the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	No
7	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";	It is a related party transaction and is carried on arm's length basis.
8	In case of issuance of shares to the parties, details of issue price, class of shares issued;	Not Applicable
9	In case of loan agreements: i) details of lender/borrower ii) nature of the loan	Lender: Moki Financial Services ("a partnership firm") Borrower: Pharmaids Pharmaceuticals Limited
	iii) total amount of loan granted/taken	Nature of loan: Unsecured Loan



	iv) total amount outstanding v) date of execution of the loan agreement/sanction letter vi) details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis;	Amount of Loan: Rs 1,00,00,000/- (Rupees One Crore) to be availed in one or more tranches. Date of Execution of agreement: 10 th July 2024 Security provided if any: Not applicable as it is an Unsecured Loan.
10	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	Not Applicable
11	In case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement. b) nature of the agreement. c) date of execution of the agreement. details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable

For Pharmaids Pharmaceuticals Limited

Kaushik Kumar (Company Secretary & Head-Legal)